Hematology-Oncology
Beyond Blast Counts: How Menin Inhibition Redefines AML Immunophenotypes and Survival
This study explores how the menin inhibitor revumenib induces significant immunophenotypic shifts in AML patients. Results show that over 50% of patients undergo lineage changes, and achieving MRD negativity remains the strongest predictor
